Study: Avastin combo doesn't extend stomach cancer patients' survival

02/24/2010 | American City Business Journals

A late-stage trial showed that Genentech's Avastin did not prolong overall survival of patients with inoperable, advanced or metastatic stomach cancer when administered in combination with ciaplatin and Roche Holding's Xeloda. Avastin also is being tested for other forms of cancer, including ovarian.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC